INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Provision of written informed consent (by patient  │ Provision of written informed consent (by patient  │     100 │
│ or appropriate designee according to local         │ or appropriate designee according to local         │         │
│ regulations) prior to any study specific           │ regulations) prior to any study specific           │         │
│ procedures                                         │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Aged 18 years or older, male or female             │ Aged 18 years or older, male or female             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of previous myocardial infarction (MI)     │ History of previous myocardial infarction (MI)     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of coronary revascularization, i.e.,       │ History of coronary revascularization, i.e.,       │     100 │
│ percutaneous coronary intervention (PCI) or        │ percutaneous coronary intervention (PCI) or        │         │
│ coronary artery bypass graft (CABG), not including │ coronary artery bypass graft (CABG), not including │         │
│ the elective PCI during the index hospitalization  │ the elective PCI during the index hospitalization  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented history of type 2 diabetes mellitus     │ Documented history of type 2 diabetes mellitus     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Post-procedural thrombolysis in myocardial         │ Post-procedural thrombolysis in myocardial         │     100 │
│ infarction (TIMI) grade 3 flow in treated vessels  │ infarction (TIMI) grade 3 flow in treated vessels  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Negative cardiac troponin test before the index    │ Negative cardiac troponin test before the index    │     100 │
│ elective PCI                                       │ elective PCI                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Taking Clopidogrel 75 mg daily dose for at least 7 │ Taking Clopidogrel 75 mg daily dose for at least 7 │     100 │
│ days or taking Clopidogrel 75 mg daily dose for    │ days or taking Clopidogrel 75 mg daily dose for    │         │
│ less than 7 days but with 300 to 600 mg            │ less than 7 days but with 300 to 600 mg            │         │
│ Clopidogrel loading dose before PCI                │ Clopidogrel loading dose before PCI                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Taking acetylsalicylic acid (ASA) 100 mg daily     │ Taking acetylsalicylic acid (ASA) 100 mg daily     │     100 │
│ treatment for at least 7 days or taking ASA 100 mg │ treatment for at least 7 days or taking ASA 100 mg │         │
│ daily dose for less than 7 days but with 300 mg    │ daily dose for less than 7 days but with 300 mg    │         │
│ ASA loading dose before PCI                        │ ASA loading dose before PCI                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ have a negative urine or blood pregnancy test at   │ have a negative urine or blood pregnancy test at   │     100 │
│ enrolment and prior to randomization               │ enrolment and prior to randomization               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ currently be using a hormonal contraceptive and    │ currently be using a hormonal contraceptive and    │     100 │
│ agree to continue its use in addition to using     │ agree to continue its use in addition to using     │         │
│ double-barrier local contraception (i.e., intra-   │ double-barrier local contraception (i.e., intra-   │         │
│ uterine device plus spermicidal and condom for     │ uterine device plus spermicidal and condom for     │         │
│ male partner) from screening through study         │ male partner) from screening through study         │         │
│ completion                                         │ completion                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of stable angina pectoris with             │ History of stable angina pectoris with             │      99 │
│ angiographic evidence of CAD (diameter stenosis ≥  │ angiographic evidence of CAD (diameter stenosis =  │         │
│ 50%) in major, i.e., left main, left anterior      │ 50%) in major, i.e., left main, left anterior      │         │
│ descending, left circumflex, and right coronary    │ descending, left circumflex, and right coronary    │         │
│ arteries                                           │ arteries                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Post-procedural residual diameter stenosis of the  │ Post-procedural residual diameter stenosis of the  │      99 │
│ treated lesions \< 20% in patients with stent      │ treated lesions < 20% in patients with stent       │         │
│ implantation or \< 50% in those with balloon       │ implantation or < 50% in those with balloon        │         │
│ angioplasty                                        │ angioplasty                                        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Increased bleeding risk including                  │ History of previous myocardial infarction (MI)     │      33 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Aged 18 years or older, male or female             │      34 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ platelet count less than 100,000/mm3 or hemoglobin │ Negative cardiac troponin test before the index    │      35 │
│ \< 10 g/dL                                         │ elective PCI                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ sustained uncontrolled hypertension (systolic      │ Provision of written informed consent (by patient  │      36 │
│ blood pressure \[SBP\] \> 180 mmHg or diastolic    │ or appropriate designee according to local         │         │
│ blood pressure \[DBP\] \> 100 mmHg)                │ regulations) prior to any study specific           │         │
│                                                    │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Contraindication or other reason that ASA,         │ currently be using a hormonal contraceptive and    │      38 │
│ Clopidogrel, or Ticagrelor should not be           │ agree to continue its use in addition to using     │         │
│ administered (e.g., hypersensitivity, active       │ double-barrier local contraception (i.e., intra-   │         │
│ bleeding \[including active pathological           │ uterine device plus spermicidal and condom for     │         │
│ bleeding\], any bleeding tendency \[coagulation    │ male partner) from screening through study         │         │
│ defects\], moderate and severe hepatic impairment, │ completion                                         │         │
│ risk of bradycardia, chronic obstructive pulmonary │                                                    │         │
│ disease, chronic or active asthma, hyperuricemia,  │                                                    │         │
│ gout, etc.)                                        │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant therapy with moderate or strong        │ Provision of written informed consent (by patient  │      39 │
│ cytochrome P-450 (CYP) 3A inhibitors, CYP 3A       │ or appropriate designee according to local         │         │
│ substrates with narrow therapeutic index, or       │ regulations) prior to any study specific           │         │
│ strong CYP 3A inducers during study period         │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ recent (within 30 days of screening)               │ History of previous myocardial infarction (MI)     │      39 │
│ gastrointestinal (GI) bleeding                     │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patient requires dialysis or has a creatinine      │ currently be using a hormonal contraceptive and    │      39 │
│ clearance (Clcr) \< 30 mL/min as calculated by the │ agree to continue its use in addition to using     │         │
│ Cockcroft-Gault equation: Clcr = (140 - Age) × WT  │ double-barrier local contraception (i.e., intra-   │         │
│ / (72 × Scr) (× 0.85 for females), where WT is     │ uterine device plus spermicidal and condom for     │         │
│ weight in kg, Scr is serum creatinine in mg/dL     │ male partner) from screening through study         │         │
│                                                    │ completion                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Females with childbearing potential (i.e., females │ Post-procedural residual diameter stenosis of the  │      40 │
│ who are not post-menopausal or surgically sterile) │ treated lesions < 20% in patients with stent       │         │
│ must                                               │ implantation or < 50% in those with balloon        │         │
│                                                    │ angioplasty                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of parenteral antithrombotic agents, e.g.,     │ Provision of written informed consent (by patient  │      40 │
│ glycoprotein IIb/IIIa inhibitors (GPIs),           │ or appropriate designee according to local         │         │
│ bivalirudin, unfractionated heparin, enoxaparin or │ regulations) prior to any study specific           │         │
│ fondaparinux within 24 hours of screening          │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant therapy with moderate or strong CYP    │ Provision of written informed consent (by patient  │      40 │
│ 2C19 inhibitors, CYP 2C19 substrates with narrow   │ or appropriate designee according to local         │         │
│ therapeutic index, or strong CYP 2C19 inducers     │ regulations) prior to any study specific           │         │
│ during study period                                │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ recent (within 30 days of screening) major trauma  │ Aged 18 years or older, male or female             │      40 │
│ or major surgery                                   │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ inability to discontinue required concomitant      │ Provision of written informed consent (by patient  │      40 │
│ therapy with non-selective non-steroidal anti-     │ or appropriate designee according to local         │         │
│ inflammatory drugs (NSAIDs) at screening           │ regulations) prior to any study specific           │         │
│                                                    │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients that are scheduled for CABG during the    │ have a negative urine or blood pregnancy test at   │      40 │
│ study period                                       │ enrolment and prior to randomization               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At least 24 hours after but within 14 days of      │ History of coronary revascularization, i.e.,       │      41 │
│ angiographically successful elective PCI without   │ percutaneous coronary intervention (PCI) or        │         │
│ complications                                      │ coronary artery bypass graft (CABG), not including │         │
│                                                    │ the elective PCI during the index hospitalization  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Patients who had acute coronary syndrome (ACS)     │ have a negative urine or blood pregnancy test at   │      41 │
│ within 12 months of screening                      │ enrolment and prior to randomization               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of any oral antithrombotic agents, with the    │ Post-procedural residual diameter stenosis of the  │      41 │
│ exception of Clopidogrel and ASA, within 30 days   │ treated lesions < 20% in patients with stent       │         │
│ of screening                                       │ implantation or < 50% in those with balloon        │         │
│                                                    │ angioplasty                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another investigational drug or   │ Provision of written informed consent (by patient  │      41 │
│ device study within 30 days of screening           │ or appropriate designee according to local         │         │
│                                                    │ regulations) prior to any study specific           │         │
│                                                    │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Occurrence of myocardial infarction (MI) related   │ History of coronary revascularization, i.e.,       │      42 │
│ to index elective PCI (type 4a MI) or myocardial   │ percutaneous coronary intervention (PCI) or        │         │
│ infarction related to stent thrombosis (type 4b    │ coronary artery bypass graft (CABG), not including │         │
│ MI) according to the Third Universal Definition of │ the elective PCI during the index hospitalization  │         │
│ Myocardial Infarction                              │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any other indications (e.g., atrial fibrillation,  │ Taking acetylsalicylic acid (ASA) 100 mg daily     │      42 │
│ prosthetic heart valve, venous thromboembolism,    │ treatment for at least 7 days or taking ASA 100 mg │         │
│ ventricular thrombosis, et al) for antithrombotic  │ daily dose for less than 7 days but with 300 mg    │         │
│ treatment other than ASA 100 mg daily, Clopidogrel │ ASA loading dose before PCI                        │         │
│ and Ticagrelor during study period                 │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ any history of intracranial, intraocular,          │ History of previous myocardial infarction (MI)     │      42 │
│ retroperitoneal, or spinal bleeding                │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ history of hemorrhagic disorders that can increase │ History of stable angina pectoris with             │      42 │
│ the risk of bleeding, e.g., haemophilia, von       │ angiographic evidence of CAD (diameter stenosis =  │         │
│ Willebrand's disease                               │ 50%) in major, i.e., left main, left anterior      │         │
│                                                    │ descending, left circumflex, and right coronary    │         │
│                                                    │ arteries                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any acute or chronic unstable conditions in the    │ currently be using a hormonal contraceptive and    │      43 │
│ past 30 days or other conditions which, in the     │ agree to continue its use in addition to using     │         │
│ opinion of the investigator, may either put the    │ double-barrier local contraception (i.e., intra-   │         │
│ patient at risk or influence the result of the     │ uterine device plus spermicidal and condom for     │         │
│ study (e.g., active cancer, risk for non-          │ male partner) from screening through study         │         │
│ compliance, risk for being lost to follow-up)      │ completion                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Recent (within 30 days of screening) blood         │ have a negative urine or blood pregnancy test at   │      43 │
│ donation                                           │ enrolment and prior to randomization               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of intolerance to ASA, Clopidogrel or      │ History of previous myocardial infarction (MI)     │      45 │
│ Ticagrelor                                         │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Involvement in the planning and conduct of the     │ Provision of written informed consent (by patient  │      45 │
│ study (applies to investigators, contract research │ or appropriate designee according to local         │         │
│ organization staff, and study site staff)          │ regulations) prior to any study specific           │         │
│                                                    │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known pregnancy, breast-feeding, or intend to      │ Provision of written informed consent (by patient  │      45 │
│ become pregnant during the study period            │ or appropriate designee according to local         │         │
│                                                    │ regulations) prior to any study specific           │         │
│                                                    │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of drug addiction or alcohol abuse in the  │ History of previous myocardial infarction (MI)     │      46 │
│ previous 2 years                                   │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Documented stable coronary artery disease (CAD)    │ Documented history of type 2 diabetes mellitus     │      48 │
│ fulfilling any of the following                    │                                                    │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════╤═════════════════╤═════════╕
│ Personal Criteria                      │ CHIA Criteria   │   Score │
╞════════════════════════════════════════╪═════════════════╪═════════╡
│ Aged 18 years or older, male or female │ NA              │       5 │
╘════════════════════════════════════════╧═════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 48
Average Levenshtein Ratio of individual lines: 57.74418604651163
OverAll Ratio: 52.872093023255815
